Search
Now showing items 1-7 of 7
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
(2020-07)
Background
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine ...
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
(2020-12)
Background
Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity ...
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
(2020-12)
More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein ...
Will COVID-19 be the coming of age for point-of-care testing?
(2020-09)
BACKGROUND
As countries deal with the COVID-19
pandemic in varying ways, one area
of agreement is the need to test for the
COVID-19 virus in as many people as
possible. Beeching et al have rightly
pointed out that ...
The neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives
(2021-02)
There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2.
In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature ...
The Impact of COVID-19 on the Cancer Care of Adolescents and Young Adults and Their Well-Being: Results From an Online Survey Conducted in the Early Stages of the Pandemic
(2020-07)
The COVID-19 pandemic is rapidly evolving, and we learn new details every day. Even though the disrup-tions in our daily routines and health care systems pose many challenges, therein lie many ...
Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19
(2020-04)
Moving diagnostic testing for COVID-19 from laboratory settings to the point of care is potentially transformative in the rate and quantity of testing that could be performed. Eleven diagnostic tests that are potentially ...